相关实验视频
Updated: Jul 28, 2025

08:47
Endoscopic Cholesteatoma Surgery
Published on: January 19, 2022
10.3K
在使用卡普兰-梅尔方法获得胆固醇瘤中复发的时间分析
Takara Nakazawa1, Yutaka Yamamoto, Kazuki Kanno
1Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan.
概括
获得性胆固醇瘤的复发,特别是软性胆固醇瘤的复发,可以在手术后长达5年发生. 超时胆固醇瘤的复发率高于残留疾病,影响了随访持续时间的估计.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 外科手术的结果
- 流行病学 流行病学
背景情况:
- 获得性胆固醇瘤是一种常见的中耳疾病.
- 了解复发模式对于有效的患者管理和随访至关重要.
- 以前的研究还没有完全阐明胆固醇瘤复发的时间趋势.
研究的目的:
- 分析获得性胆固醇瘤复发的时间趋势.
- 为了确定影响胆固醇瘤复发的因素.
- 在胆固醇瘤手术后提供最佳后续策略的信息.
主要方法:
- 对256名首次接受胆固醇瘤手术的患者进行了回顾性观察性研究.
- 卡普兰-梅尔生存分析用于计算累积无复发率.
- 分析将复发与随访期,病理生理学,疾病程度和特定病理学相关联.
主要成果:
- 帕斯软性胆固醇瘤与耳腔进展显示,复发的可能性很高.
- 与残留疾病相比,Pars tensa cholesteatoma的复发率更高.
- 两种类型的复发发病率在手术后的3年内都增加;帕斯软性胆固醇瘤延伸到乳头/耳腔的复发发病率在5年内复发.
结论:
- 获得性胆固醇瘤的复发模式根据位置和程度而异.
- 卡普兰-梅尔分析提供了对长期复发趋势的见解.
- 结果可以精确估计患者随访所需的持续时间.
相关概念视频
Kaplan-Meier Approach
197
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
197
Comparing the Survival Analysis of Two or More Groups
229
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
229
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Introduction To Survival Analysis
301
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
301
Actuarial Approach
101
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
101
Assumptions of Survival Analysis
163
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
163

